Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
SPARCNSESun Pharma Advanced Research Company Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Tue, 3 Feb, 2026 · 08:35 IST

SPARC receives FDA Priority Review Voucher tied to Sezaby approval

Regulatory Product ApprovalBusiness Updates View source PDFExplain this filing

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.7%Reaction day
₹132.70
prior close
₹143.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+3.7%+1.0% vs market
Pharmaceuticals peers, median of 157sector+2.6%+2.2% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.2
10m
-1.8
15m
-2.6
30m
-3.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.7+3.7+1.0+2.6+2.2
Next day
+6.2+5.1+1.1+2.5+3.7
2d
+6.2+4.0+2.1+1.6+4.6
3d
+4.9+3.2+1.7+1.1+3.8
4d
+4.0+5.9-1.9+2.9+1.1
5d
+6.1+6.9-0.8+3.1+3.0
1w
+1.7+5.9-4.2+2.6-0.9
15d
-3.5+2.1-5.6-0.6-3.0
1m
-7.2-3.5-3.8-2.6-4.7
2m
-7.2-4.2-2.9-4.7-2.5
3m
+5.5+10.9-5.5+4.0+1.5
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SPARC announced receipt of a Rare Pediatric Disease Priority Review Voucher from the US FDA tied to the approval of Sezaby. Sezaby is a benzyl alcohol and propylene glycol free phenobarbital sodium injection for neonatal seizures. The PRV is tradable and can be redeemed to get priority review on a future drug application or sold to another company. SPARC said it plans to use the voucher to accelerate its drug pipeline.

Likely market impact

Positive: Sezaby approval plus a valuable tradable voucher that can fast track future drug reviews or be sold for revenue.